New
HealthMore in Health→
In Vivo BCMA CAR-T Shows Limited Durability in Myeloma Follow-Up
Key Takeaways
- Nature Medicine published an extended follow-up of four patients with relapsed or refractory multiple myeloma treated with in vivo BCMA CAR-T cells.
- The reported outcome indicates limited duration of response among the four participants.
- In vivo CAR-T generates engineered T cells inside the patient rather than through external manufacturing, potentially reducing cost and turnaround time.
- BCMA is a validated target on myeloma plasma cells, but durability remains the central unresolved question for the approach.
DE
DT Editorial Team··via nature.com